Pulmonary Hypertension Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Bosentan in Patients With Mildly Symptomatic Pulmonary Arterial Hypertension (PAH)
Verified date | August 2011 |
Source | Actelion |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.
Status | Completed |
Enrollment | 185 |
Est. completion date | February 2011 |
Est. primary completion date | November 2006 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 12 Years and older |
Eligibility |
Inclusion Criteria: - PAH NYHA Class II - Significant elevation of mean pulmonary arterial pressure - Significant elevation of pulmonary vascular resistance at rest - Limited 6-minute walk distance Exclusion Criteria: - PAH secondary to portal hypertension, complex congenital heart disease or reverse shunt - Restrictive or obstructive lung disease - Significant vasoreactivity - Treatments for PAH (within 4 weeks of randomization) |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | The Prince Charles Hospital | Brisbane | |
Australia | Royal Prince Albert Hospital | Camperdown | |
Australia | St. Vincent's Hospital | Darlinghurst | |
Austria | General Hospital of Vienna | Vienna | |
Belgium | UZ Gasthuisberg | Leuven | |
Canada | University of Calgary | Calgary | Alberta |
Canada | University of Alberta | Edmonton | Alberta |
Canada | Halifax Infirmary | Halifax | Nova Scotia |
Canada | Victoria Medical Centre | Hamilton | Ontario |
Canada | Centre de Pneumologie de L'Hospital Laval | Sainte Foy | Quebec |
Canada | Toronto General Hospital | Toronto | Ontario |
China | Queen Mary Hospital | Hong Kong | |
Czech Republic | Interni klinika VFN | Prague | |
France | Marseille-Timone | Marseille | |
Germany | Universitat Greifswald | Greifswald | |
Germany | Universitat Greifswald | Greifswald | |
Germany | Universitarsklinikum Hamburg-Eppendorf | Hamburg | |
Germany | Medizinische Universitatsklinik | Heidelberg | |
Germany | Universitatsklinikim Leipzig | Leipzig | |
Germany | Klinikum der Universitat Regensburg | Regensburg | |
Italy | Policlinico S. Orsola-Malpighi | Bologna | |
Netherlands | VU Medisch Centrum | Amsterdam | |
Netherlands | University Hospital Maastricht | Maastricht | |
Spain | Hospital Clinic | Barcelona | |
Spain | Hospital Valle d'Hebron | Barcelona | |
Spain | Hospital 12 de Octubre | Madrid | |
Switzerland | Zurich University Hospital | Zurich | |
United Kingdom | Papworth Hospital | Cambridge | |
United States | University of Michigan | Ann Arbor | Michigan |
United States | University of Alabama-Birmingham | Birmingham | Alabama |
United States | Tufts- New England Medical Center | Boston | Massachusetts |
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
United States | St. Paul University Hospital | Dallas | Texas |
United States | Harbor UCLA Medical Center | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
Actelion |
United States, Australia, Austria, Belgium, Canada, China, Czech Republic, France, Germany, Italy, Netherlands, Spain, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | exercise capacity | Baseline to end of study | No | |
Primary | cardiac hemodynamics | Baseline to end of study | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01950585 -
Hydroxyurea in Pulmonary Arterial Hypertension
|
Early Phase 1 | |
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Completed |
NCT03649932 -
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
|
Phase 1 | |
Recruiting |
NCT04554160 -
Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
|
||
Enrolling by invitation |
NCT03683186 -
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
|
Phase 3 | |
Completed |
NCT01894035 -
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
|
||
Not yet recruiting |
NCT04083729 -
Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy
|
N/A | |
Completed |
NCT02216279 -
Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension
|
Phase 2 | |
Terminated |
NCT02246348 -
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
|
N/A | |
Terminated |
NCT02243111 -
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
|
N/A | |
Completed |
NCT02821156 -
Study on the Use of Inhaled NO (iNO)
|
N/A | |
Recruiting |
NCT01913847 -
Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT06240871 -
Contrast Enhanced PA Pressure Measurements
|
||
Completed |
NCT02377934 -
Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
|
||
Recruiting |
NCT01091012 -
Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT01463514 -
Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension
|
N/A | |
Completed |
NCT00739375 -
The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension.
|
Phase 1 | |
Completed |
NCT01484899 -
Smoking: a Risk Factor for Pulmonary Arterial Hypertension?
|
N/A | |
Completed |
NCT02275793 -
The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
|